# Nurix Therapeutics Posts $673.1 Million Q3 Revenue on Major Roche Deal

- URL: https://stocks.freetheai.org/news/nurix-therapeutics-posts-673-1-million-q3-revenue-on-major-roche-deal-daac95
- Published: 2026-10-12T20:05:00Z
- Category: earnings; sentiment: mixed; impact: high
- Symbols: [NASDAQ:NRIX](https://stocks.freetheai.org/symbols/NASDAQ-NRIX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Nurix Therapeutics, Inc. (NRIX) reported Q3 2026 revenue of $673.1 million, up from $7.9 million in the prior-year period. Net income reached $549.8 million for the quarter. The sharp increase was driven primarily by $653.2 million in licensing revenue tied to a collaboration with Roche, which included a $700 million upfront payment.

The licensing revenue significantly strengthens the balance sheet, bringing total cash and securities to $1.1 billion. This extends the company operating runway into the second half of 2029 and reduces near-term financing risks. Additionally, Nurix earned a $10.0 million milestone payment from Sanofi, further validating its partnered pipeline.

Looking ahead, investors will focus on progress in the clinical pipeline, including the late-stage Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg against pirtobrutinib. Key value catalysts will depend on Phase 3 safety and efficacy readouts, as well as revenue clarity beyond finite licensing fees.

## Key points

- Nurix Therapeutics reported third-quarter 2026 revenue of $673.1 million, compared to $7.9 million in the prior year.
- Net income for the quarter reached $549.8 million, driven by $653.2 million in licensing revenue from Roche.
- Cash and securities reached $1.1 billion following a $700 million upfront payment, extending the cash runway into H2 2029.
- The company started the Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg against pirtobrutinib.
- Nurix earned a $10.0 million milestone payment from Sanofi.

## Questions and answers

### What were Nurix Therapeutics Q3 2026 financial results?

Nurix Therapeutics reported Q3 2026 revenue of $673.1 million and net income of $549.8 million. Revenue surged from $7.9 million in the year-ago period, primarily driven by $653.2 million in licensing revenue from a collaboration with Roche.

### How much cash does Nurix Therapeutics have?

Nurix Therapeutics holds $1.1 billion in cash and securities following a $700 million upfront payment from Roche. This cash position extends the company runway into the second half of 2029.

### What is the next clinical milestone for Nurix Therapeutics?

Nurix has started the Phase 3 DAYBreak CLL-306 trial to evaluate bexobrutideg against pirtobrutinib. Key value drivers will depend on upcoming Phase 3 efficacy and safety readouts.